In inoperable malignancy, pain relief with opioids is often inadequate. Nerve block procedures may improve symptom control. Our aim was to assess celiac plexus block (CPB) and thoracoscopic splanchnicectomy (TS) in patients receiving appropriate medical management (MM). Methods: Patients with confirmed irresectable malignancy of the pancreas or upper abdominal viscera who required opioid analgesia were randomized to MM alone, MM+CPB, or MM+TS. Randomization was stratified by treatment centre, tumour type and previous opioid medication. The primary endpoint was pain relief at 2 months. Results: 65 patients (58 pancreas cancer) were randomized, 18 withdrew or died within 2 months. Effective pain relief was achieved in only one third of subjects at 2 weeks, and just under half at 2 months (MM: 6/19 and 5/12 evaluable patients; CPB: 5/14 and 5/9; TS 4/14 and 4/11). There were no significant differences between the groups in pain scores or opioid consumption, and there was no correlation between continued use of opioids and effective pain relief. Discussion: Previous randomized studies have shown small differences in pain scores, but no difference in opioid consumption and quality of life. The absence of any benefit from interventions in the present study questions their value.

Keywords:
Celiac plexus block, Medical management, Pain management, Protocol-driven opioid analgesia, Thoracoscopic splanchnicectomy
1.
Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK: Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993;217:447–455.
2.
Kawamata M, Ishitani K, Ishikawa K, Sasaki H, Ota K, Omote K, et al: Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Pain 1996;64:597–602.
3.
Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S: Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 1998;85:199–201.
4.
Eisenberg E, Carr DB, Chalmers TC: Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995;80:290–295.
5.
Mercadante S: Celiac plexus block versus analgesics in pancreatic cancer pain. Pain 1993;52:187–192.
6.
Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, et al: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092–1099.
7.
Cuschieri A, Shimi SM, Crosthwaite G, Joypaul V: Bilateral endoscopic splanchnicectomy through a posterior thoracoscopic approach. J R Coll Surg Edinb 1994;39:44–47.
8.
Le Pimpec BF, Chapuis O, Riquet M, Cuttat JF, Peillon C, Mouroux J, et al: Thoracoscopic splanchnicectomy for control of intractable pain in pancreatic cancer. Ann Thorac Surg 1998;65:810–813.
9.
Lin CC, Mo LR, Lin YW, Yau MP: Bilateral thoracoscopic lower sympathetic-splanchnicectomy for upper abdominal cancer pain. Eur J Surg Suppl 1994;572:59–62.
10.
Melki J, Riviere J, Roullee N, Soury P, Peillon C, Testart J: Thoracic splanchnicectomy under video thoracoscopy (in French). Presse Méd 1993;22:1095–1097.
11.
Sastre B, Carabalona B, Crespy B, Delpero JR, Sielezneff I, Michotey G: Transhiatal bilateral splanchnicotomy for pain control in pancreatic cancer: basic anatomy, surgical technique, and immediate results in 51 cases. Surgery 1992;111:640–646.
12.
Worsey J, Ferson PF, Keenan RJ, Julian TB, Landreneau RJ: Thoracoscopic pancreatic denervation for pain control in irresectable pancreatic cancer. Br J Surg 1993;80:1051–1052.
13.
Davies DD: Incidence of major complications of neurolytic coeliac plexus block. J R Soc Med 1993;86:264–266.
14.
Ihse I, Zoucas E, Gyllstedt E, Lillo-Gil R, Andren-Sandberg A, Russell C, et al: Bilateral thoracoscopic splanchnicectomy: effects on pancreatic pain and function. Ann Surg 1999;230:785–791.
15.
Selzer DJ, Howard TJ, Kesler KA: Management of chylothorax after thoracoscopic splanchnicectomy. J Laparoendosc Adv Surg Tech A 1999;9:273–276.
16.
Pietrabissa A, Vistoli F, Carobbi A, Boggi U, Bisa M, Mosca F: Thoracoscopic splanchnicectomy for pain relief in unresectable pancreatic cancer. Arch Surg 2000;135:332–335.
17.
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277–284.
18.
Lin WC, Lum TY, Mehr DR, Kane RL: Measuring pain presence and intensity in nursing home residents. J Am Med Dir Assoc 2006;7:147–153.
19.
Hoekstra J, Bindels PJ, van Duijn NP, Schade E: The symptom monitor. A diary for monitoring physical symptoms for cancer patients in palliative care: feasibility, reliability and compliance. J Pain Symptom Manage 2004;27:24–35.
20.
Jensen MP: The validity and reliability of pain measures in adults with cancer. J Pain 2003;4:2–21.
21.
Yates PM, Edwards HE, Nash RE, Walsh AM, Fentiman BJ, Skerman HM, et al: Barriers to effective cancer pain management: a survey of hospitalized cancer patients in Australia. J Pain Symptom Manage 2002;23:393–405.
22.
Sutton LM, Porter LS, Keefe FJ: Cancer pain at the end of life: a biopsychosocial perspective. Pain 2002;99:5–10.
23.
Campbell LC, Clauw DJ, Keefe FJ: Persistent pain and depression: a biopsychosocial perspective. Biol Psychiatry 2003;54:399–409.
© 2010 S. Karger AG, Basel and IAP
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.